Skip to main content

FDA grants Novartis exclusivitiy for blood pressure medication for children

8/20/2007

BASEL, Switzerland Novartis announced that the Food and Drug Administration has granted Diovan (valsartan) pediatric exclusivity based on studies conducted in children with high blood pressure.

Nearly 5 percent of U.S. children and adolescents may have high blood pressure, according to Novartis. The company added that it anticipates an FDA decision on adding a pediatric indication to Diovan’s labeling by the end of the year.

Diovan is Novartis’ top-selling brand drug, with $2.4 billion in sales during the first half of 2007, the company reported in its second-quarter earnings statement last month.

X
This ad will auto-close in 10 seconds